Life Science Investing Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
Life Science Investing Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
Life Science Investing Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial
Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
UPDATE - Critical Metals Corp (NASDAQ: CRML) Secures Another Significant Tanbreez Offtake Agreement for 15% of its Production with Leading U.S. Vertically Integrated Rare Earth Company, REalloys Inc.
